Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462786 | 0.80 | PTGS2 (0.38) | PTGS2PTGS1KDM4EALDH1A1HPGD | |
| SCHEMBL10527035 | 0.74 | XDH (0.47) | XDHPOLBALDH1A1HPGDGPR84 | |
| SCHEMBL22591293 | 0.73 | BAZ2B (0.43) | PTGS2ALDH1A1HPGDHSD17B10PGR | |
| SCHEMBL5728560 | 0.71 | GPR119 (0.51) | HSD17B10 | |
| SCHEMBL433705 | 0.67 | CASP1 (0.46) | PTGS2KDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL3518973 | 0.67 | PGR (0.38) | PTGS2KDM4EALDH1A1TSHRMAPK1 | |
| SCHEMBL4247250 | 0.65 | TSHR (0.55) | XDHKDM4EALDH1A1HPGDTSHR | |
| SCHEMBL9373869 | 0.65 | RECQL (0.66) | XDHPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL23792337 | 0.64 | PGR (0.38) | PTGS2PTGS1KDM4EALDH1A1HPGD | |
| SCHEMBL31674157 | 0.64 | HSD17B1 (0.41) | PTGS2PTGS1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2595966-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | Onyx Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2595966-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | Onyx Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | GLUL, QPCT, ASNS | XDH 670/4885PTGS2 376/4885POLB 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.